Evidence map›Paper›PMID 37180052›Full record

ArticleClinical and translational radiation oncology2023

Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1.

Agnes Oetting, Sabrina Christiansen, Fruzsina Gatzemeier, Sabrina Köcher, Lara Bußmann, Arne Böttcher, Katharina Stölzel, Anna Sophie Hoffmann, Nina Struve, Malte Kriegs and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Agnes OettingDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Sabrina ChristiansenDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Fruzsina GatzemeierDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Sabrina KöcherDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Lara BußmannDepartment of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.
Arne BöttcherDepartment of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.
Katharina StölzelDepartment of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.
Anna Sophie HoffmannDepartment of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.
Nina StruveDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Malte KriegsDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Cordula PetersenDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Christian BetzDepartment of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.
Kai RothkammDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Henrike Barbara ZechDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Thorsten RieckmannDepartment of Radiotherapy, University Medical Center Hamburg Eppendorf, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: In head and neck squamous cell carcinoma (HNSCC), tumors negative for Human Papillomavirus (HPV) remain a difficult to treat entity and the morbidity of current multimodal treatment is high. Radiotherapy in combination with molecular targeting could represent suitable, less toxic treatment options especially for cisplatin ineligible patients. Therefore, we tested dual targeting of PARP and the intra-S/G2 checkpoint through Wee1 inhibition for its radiosensitizing capacity in radioresistant HPV-negative HNSCC cells. Materials and methods: Three radioresistant HPV-negative cell lines (HSC4, SAS, UT-SCC-60a) were treated with olaparib, adavosertib and ionizing irradiation. The impact on cell cycle, G2 arrest and replication stress was assessed through flow cytometry after DAPI, phospho-histone H3 and γH2AX staining. Long term cell survival after treatment was determined through colony formation assay and DNA double-strand break (DSB) levels were assessed through quantification of nuclear 53BP1 foci in cell lines and patient-derived HPV± tumor slice cultures. Results: Wee1 and dual targeting induced replication stress but failed to effectively inhibit radiation-induced G2 cell cycle arrest. Single as well as combined inhibition increased radiation sensitivity and residual DSB levels, with the largest effects induced through dual targeting. Dual targeting also enhanced residual DSB levels in patient-derived slice cultures from HPV-negative but not HPV+ HNSCC (5/7 vs. 1/6). Conclusion: We conclude that the combined inhibition of PARP and Wee1 results in enhanced residual DNA damage levels after irradiation and effectively sensitizes radioresistant HPV-negative HNSCC cells.

Indexed as

Cell-cycle checkpointDNA repairHead and neck cancerPARPRadiosensitizationRadiotherapyWee1

Identifiers

PMID37180052
PMCPMC10172863
OpenAlexW4366524750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.